Dose Optimization of rhIL‐7‐hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor‐Mediated Recycling‐Based and Target‐Mediated Drug Disposition Pharmacokinetic Model

Dose Optimization of rhIL‐7‐hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor‐Mediated Recycling‐Based and Target‐Mediated Drug Disposition Pharmacokinetic Model

ABSTRACT Recombinant human interleukin‐7 hybrid Fc (rhIL‐7‐hyFc) is a homodimer of rhIL‐7 fused to a hyFc. Exogenous IL‐7 promotes T cell proliferation and increases lymphocyte count, making it a potential treatment option for lymphopenia and cancer. To improve therapeutic efficacy, rhIL‐7‐hyFc was...

Full description

Saved in:
Bibliographic Details
Main Authors: Hye Seon Jeon, Sang Won Lee, Woojin Jung, Heeyoon Jung, Donghoon Choi, Mi‐Sun Byun, Hwi‐yeol Yun, Soyoung Lee, Anhye Kim, Jung‐woo Chae, Howard Lee
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Clinical and Translational Science
Subjects:
lymphopenia
optimal dosing for clinical trials
rhIL‐7‐hyFc
semi‐mechanistic model
Online Access:https://doi.org/10.1111/cts.70252
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70252

Similar Items